Pfizer has recently cancelled its clinical trial on advanced Non...

Pfizer has recently cancelled its clinical trial on advanced Non Small Cell Lung Cancer with Coleys TLR9 primer in combination with standard cytotoxic chemotherapy. An intrim look showed no improvement. They did not state if side effcts were an issue, although they did say the risk/benefit profile did not justify continuation.
http://phx.corporate-ir.net/phoenix.zhtml?c=148035&p=irol-newsArticle&ID=1017688&highlight=

Preclinicals with Coramsine and Ideras Imoxine(another TLR9 primer) have demonstrated to be a powerful combination, as demonstrated by the mice that beat Mesothelioma and remained immune from reintroduction of the cancer. This looks another area where Coramsine may be superior to current treatments. With Coramsines ability to start an immune response against the tumour, it is perhaps able to focus the massive unfocused immune response brought on by the TLR9 agonist. The Toll Like Receptors(TLR9) are found on the Dendretic cells of the immune system and identify foreign pathogens such as bacteria. The Dendretic cells direct the immune attack, the traffic cops of the immune system. The Imoxine is a synthetic strand of bacteria DNA that registers with the TLR9s as a massive bacteria attack. The Dendretic cells then unleash an immune cascade against the non existent bacteria. With Coramsine there doing its own thing popping cancer cells as it attacks the tumour by binding onto Solbecs patented Rhamnose Binding Protein, exposing the fragments of the cancer cells for ID by the immune system, in the case of the mice, the Mesothelioma was wiped out completely. The Pfizer trial used a similar treatment to Imoxine in combination with cytotoxics, but no improvement over the cytotoxic alone was observed. Perhaps because most of the cytotoxics are hard on the immune system, where Coramsine is not. Of course clinical trials are needed prove this.
http://www.cosmosmagazine.com/node/471

It is already known that Coramsine has the ability to down regulate the immune system cytokine IL6. Trials with other drugs on various cancers, have indicated this removes one of the cancer cells defences against anti cancer drugs. One more potential advantage over current cytotoxic chemos.
http://clincancerres.aacrjournals.org/cgi/content/abstract/12/18/5578

A clinical trial has demonstrated it is safe to use on people and some responses were seen on even the very advanced refractory(resistant to all current cancer drugs) patients in the phase 1 trial. Maximum doses were established in this trial.
http://meeting.ascopubs.org/cgi/content/abstract/24/18_suppl/2070?maxtoshow=&HITS=10&hits=10&RESULTFORMAT=&fulltext=millward&searchid=1&FIRSTINDEX=0&volume=24&issue=18_suppl&resourcetype=HWCIT&eaf

Now they just need the TGA to give the OK for a phase 2 clinical trial on the target cancers to begin. Then progress can be made to bring this drug to the patients. Wouldnt that be nice.
Good luck to holders. I think there are some big results ahead. All IMHO. I am not an expert in this field so do your own DD.